8-K: INmune Bio Submits Phase 2 Alzheimer's Trial Results

INmune Bio submitted its Phase 2 MINDFuL trial results for XPro1595 in early Alzheimer's disease to npj Dementia, showing promise in a specific patient subgroup despite not meeting the primary endpoint in the overall population.

Summary

• INmune Bio Inc. announced the submission of a manuscript detailing the results of its Phase 2 MINDFuL trial for XPro1595 to npj Dementia, a Nature Portfolio journal, for peer review.
• The trial evaluated XPro1595, a selective soluble TNF neutralizer, in patients with early Alzheimer's disease and biological signs of inflammation (ADi).
• The study did not meet its primary endpoint in the overall patient population.
• A promising signal was observed in a prespecified subgroup of patients with both amyloid pathology and a high inflammatory burden (ADi population, defined by two or more biomarkers of inflammation).
• In the biomarker-enriched ADi population, XPro1595 demonstrated consistent positive trends across cognitive, neuropsychiatric, and biological endpoints.
• XPro1595 showed a complete absence of amyloid-related imaging abnormalities (ARIA), a serious side effect common with amyloid-targeting therapies, even in high-risk patients including APOE4 carriers and those on anticoagulants.
• The company believes these results support continued development of XPro1595 as a precision medicine approach for a specific subset of Alzheimer's patients.
• Regulatory feedback from the FDA is anticipated in the first quarter of 2026.

Sentiment

Score: 6

Explanation: While the primary endpoint was missed in the overall population, the positive signal in a prespecified subgroup, coupled with an excellent safety profile (absence of ARIA), provides a strong rationale for continued development and regulatory discussions. The precision medicine approach is a positive, but the overall trial miss tempers enthusiasm.

Positives

• XPro1595 demonstrated a promising signal in a prespecified subgroup of Alzheimer's patients with both amyloid pathology and a high inflammatory burden (ADi population).
• Consistent positive trends were observed across cognitive, neuropsychiatric, and biological endpoints within the ADi subgroup.
• The trial showed a complete absence of amyloid-related imaging abnormalities (ARIA), a serious side effect common with other amyloid-targeting therapies, even in high-risk patient populations.
• The favorable safety profile distinguishes XPro1595 and suggests potential for broader use, including in combination therapies.
• The subgroup data provides a strong rationale for upcoming end-of-Phase 2 discussions with regulatory authorities (FDA, EMA, MHRA).

Negatives

• The Phase 2 MINDFuL trial did not meet its primary endpoint in the overall patient population.

Risks

• Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved.
• There is no assurance that XPro1595 will be approved by the US Food and Drug Administration (FDA) or any other regulatory body.
• The company's ability to produce more drug for clinical trials.
• The availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies, and future product commercialization.
• Risks and uncertainties relating to the company's business, research, product development, regulatory approval, marketing, and distribution plans and strategies.

Future Outlook

The company anticipates continued development of XPro1595 as a precision medicine approach for Alzheimer's disease, with upcoming end-of-Phase 2 discussions with regulatory authorities (FDA, EMA, MHRA) and expected FDA feedback in Q1 2026. Management believes the subgroup analysis and strong safety profile favorably position XPro1595 for clinical trial advancement.

Management Comments

• "The publication of the MINDFuL trial results with the scientific community highlight the potential therapeutic value of our XPro platform. We are encouraged by the trial results of the subgroup analysis, in addition to the demonstrated strong safety profile, which we believe favorably positions XPro for clinical trial advancement." CJ Barnum, VP of Neuroscience at INmune Bio.
• "Data in the subgroup analysis strongly suggests XPro will benefit the trials target patient population while also providing a strong rationale for our upcoming end-of-Phase 2 discussions with regulatory authorities, including the FDA, EMA, and MHRA. We anticipate receiving regulatory feedback from the FDA in the first quarter of 2026." David Moss, CEO of INmune Bio.

Industry Context

This announcement highlights the ongoing challenge and evolving strategies in Alzheimer's disease research. While many amyloid-targeting therapies have faced safety concerns like ARIA, XPro1595's distinct mechanism (selectively neutralizing soluble TNF) and favorable safety profile, particularly the absence of ARIA, could position it as a differentiated option. The focus on a biomarker-enriched subgroup aligns with the industry trend towards precision medicine in neurodegenerative diseases, moving away from broad-population treatments towards more targeted approaches for specific patient profiles.

Comparison to Industry Standards

• XPro1595's complete absence of amyloid-related imaging abnormalities (ARIA) in its Phase 2 trial distinguishes it from several amyloid-targeting therapies, such as Biogen's Aduhelm (aducanumab) and Eisai/Biogen's Leqembi (lecanemab), which have reported ARIA as a common and serious side effect. This favorable safety profile, even in high-risk populations (APOE4 carriers, anticoagulant users, individuals with multiple cerebral microbleeds), suggests a potentially safer therapeutic option or a strong candidate for combination therapies where ARIA risk is a limiting factor for other drugs.
• The shift to a prespecified subgroup analysis for efficacy, focusing on patients with both amyloid pathology and high inflammatory burden (ADi population), aligns with the precision medicine trend seen in other therapeutic areas and is becoming increasingly relevant in complex diseases like Alzheimer's. This approach is similar to how certain cancer therapies are approved for specific biomarker-positive patient populations, aiming for higher efficacy rates in targeted groups rather than a broad, less effective approach.

Stakeholder Impact

• **Shareholders:** Potential for increased value if XPro1595 successfully advances through clinical trials for the ADi subgroup, but initial disappointment from missing the primary endpoint in the overall population may cause short-term volatility.
• **Patients with Alzheimer's Disease:** Offers a potential new therapeutic option, particularly for those with inflammation, and a safer alternative regarding ARIA compared to some existing treatments.
• **Healthcare Providers:** Provides new data on a potential treatment for Alzheimer's, informing future treatment strategies and combination therapies.
• **Regulatory Authorities:** Will be involved in discussions regarding the future clinical development and potential approval pathway for XPro1595 based on the subgroup data.

Next Steps

• Engage in end-of-Phase 2 discussions with regulatory authorities, including the FDA, EMA, and MHRA.
• Receive regulatory feedback from the FDA in the first quarter of 2026.
• Continue development of XPro1595 as a precision medicine approach for Alzheimer's disease.

Key Dates

Recommendation

The primary endpoint miss in the overall population is a significant negative, but the promising subgroup data and exceptional safety profile (absence of ARIA) provide a strong basis for continued development and regulatory engagement. The stock may experience volatility due to the mixed results. A 'hold' recommendation is appropriate as investors await further clarity from regulatory discussions and future trial designs, which could unlock significant value if the precision medicine approach proves successful.

Keywords

Alzheimer's Disease, Neuroinflammation, XPro1595, MINDFuL Trial, Phase 2, Soluble TNF Neutralizer, ADi, Biotechnology, Clinical Trial Results, INMB